• A 83-01 (ALK-5 Inhibitor): Optimizing TGF-β Pathway Assays

  2026-07-20

  A 83-01 sets the gold standard for selective ALK-5 inhibition in TGF-β signaling research. This guide translates bench protocols and troubleshooting strategies into actionable insights for organoid, EMT, and Smad pathway studies.

• TPCA-1 in Translational Inflammation Research: Beyond NF-κB

  2026-07-20

  Explore how TPCA-1, a selective IKK-2 inhibitor, enables advanced modeling of cytokine-driven inflammation and apoptosis in translational research. This article reveals novel insights linking TPCA-1's mechanism to the NF-κB/Apaf1/caspase-9 axis, informing assay design beyond current literature.

• CXCR4-Targeted Imaging and Therapy in Lymphoma: Key Advances

  2026-07-19

  This review details recent advances in CXCR4-targeted molecular imaging and precision therapy for lymphoma. By integrating peptide- and small-molecule-based CXCR4 ligands, the study demonstrates strategies for diagnosis, prognosis, and therapeutic intervention in aggressive lymphomas.

• iPSC-Derived Multilineage Organoids Enable HEV Pan-Tissue Mo

  2026-07-18

  This study establishes induced pluripotent stem cell (iPSC)-derived liver, intestinal, and brain organoids as robust, physiologically relevant models for hepatitis E virus (HEV) infection and propagation. The research demonstrates how these organoids support the full HEV life cycle, offering new insights into viral tropism, pathogenesis, and translational workflows for evaluating antiviral strategies.

• IWP-L6: Precision Porcupine Inhibitor for Wnt Pathway Studie

  2026-07-17

  IWP-L6 empowers researchers with sub-nanomolar precision to dissect Wnt signaling, enabling robust control in developmental, metabolic, and regenerative assays. This guide translates recent metabolic insights and bench-proven workflows into actionable protocols, troubleshooting, and advanced applications for reliable Wnt modulation.

• Optimized hGBA1-mRNA Drives Lysosomal GCase Restoration in G

  2026-07-17

  This study presents a rationally engineered human GBA1 mRNA that significantly boosts lysosomal β-glucocerebrosidase activity in cellular and animal Gaucher disease models. The approach demonstrates efficient mRNA-LNP delivery, sustained enzyme function, and restoration of lysosomal health, offering a promising trajectory for mRNA-based therapy development.

• (S)-(+)-Ibuprofen: COX Inhibitor Workflows for Inflammation

  2026-07-16

  (S)-(+)-Ibuprofen offers precise, reproducible COX inhibition for advanced inflammation and pain mechanism studies. This guide delivers protocol enhancements, troubleshooting strategies, and experimental insights for maximizing impact in both in vitro and in vivo research using APExBIO’s high-purity compound.

• Sodium Salicylate: Mechanistic Leverage in Tumor Stroma Repr

  2026-07-16

  This article explores how sodium salicylate, a potent NF-κB inhibitor, offers translational researchers a mechanistic and strategic edge in reprogramming the tumor stroma—especially in the context of chemoresistant pancreatic ductal adenocarcinoma (PDAC). By synthesizing evidence from advanced nanomedicine studies, experimental protocols, and APExBIO’s product intelligence, we connect the molecular intricacies of NF-κB pathway inhibition with actionable guidance for inflammation and tumor microenvironment research.

• Chemical Genetics Dissection of Jasmonate Signaling in Arabi

  2026-07-15

  This study demonstrates how bestatin, an aminopeptidase inhibitor, can be used as a chemical genetic tool to dissect jasmonate signaling pathways in Arabidopsis. By characterizing bestatin-resistant mutants, the research uncovers novel components of jasmonate-mediated defense and developmental processes, providing a model for chemical genetics in plant hormone signaling.

• Shaping Cell Fate: ATP Luminescence for Translational Impact

  2026-07-15

  This thought-leadership article empowers translational researchers with mechanistic insights and strategic guidance for leveraging luciferase-based ATP cell viability assays—centering on the Luminescent ATP Cell Viability Assay Kit I—to decode cell fate in complex disease models. By integrating recent advances in glioblastoma research with benchmarking against legacy methods, the article provides a roadmap for rapid, reproducible, and actionable cell viability measurement in modern biomedical discovery.

• Docosahexaenoic Acid (DHA): Spatial Lipidomics and Cognitive

  2026-07-14

  Explore how Docosahexaenoic Acid (DHA) restores hippocampal lipid homeostasis and mitigates postoperative cognitive dysfunction, with insights from cutting-edge spatial metabolomics. Discover the scientific depth and translational promise of this anti-inflammatory omega-3 fatty acid.

• Mubritinib Reveals OXPHOS Vulnerabilities in Acute Myeloid L

  2026-07-14

  Baccelli et al. (2019) discovered that Mubritinib selectively targets oxidative phosphorylation (OXPHOS)-dependent acute myeloid leukemia (AML) through ubiquinone-dependent inhibition of mitochondrial complex I. This work maps the metabolic heterogeneity of AML and highlights a genetically defined subgroup that is uniquely susceptible to mitochondrial disruption, opening new avenues for targeted therapy.

• PAD4-IN-2 TFA: Targeted Inhibition of Tumor NET Formation

  2026-07-13

  PAD4-IN-2 TFA (Compound 5i TFA) delivers highly selective histone H3 citrullination and NET inhibition in tumor models, enabling precision modulation of the tumor immune microenvironment. Learn how its meta-phenylboronic acid modification transforms tumor targeting, workflow design, and troubleshooting for cutting-edge cancer research.

• D-N-Acetylgalactosamine: Protocol Use in Brain Glycoprotein

  2026-07-13

  D-N-Acetylgalactosamine is a high-purity, water-soluble metabolite essential for researchers analyzing glycoprotein structures and glycosylation pathways in neurological tissues. It is not suitable for protocols needing ethanol solubility or long-term storage of solutions, so adherence to handling and storage guidelines is critical for reproducibility.

• Mubritinib (TAK 165): Rethinking Mitochondrial Targets in AM

  2026-07-12

  This thought-leadership article explores Mubritinib (TAK 165) as a precision tool for dissecting mitochondrial vulnerabilities in chemotherapy-resistant acute myeloid leukemia (AML) and KSHV-driven lymphomas. We connect mechanistic insights with actionable strategies for translational researchers, bridge cross-domain antiviral developments, and provide critical protocol guidance, all while contextualizing Mubritinib’s unique position in the evolving competitive landscape. Referencing APExBIO's flagship compound, we outline how this piece advances beyond standard product coverage.

455 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page